Sarepta Therapeutics, Inc. (FRA:AB3A)

Germany flag Germany · Delayed Price · Currency is EUR
18.43
+1.08 (6.22%)
At close: Dec 4, 2025
-84.56%
Market Cap 2.01B
Revenue (ttm) 2.06B
Net Income (ttm) -231.41M
Shares Out n/a
EPS (ttm) -2.36
PE Ratio n/a
Forward PE 10.99
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 339
Open 18.43
Previous Close 17.35
Day's Range 18.43 - 18.43
52-Week Range 8.96 - 123.70
Beta n/a
RSI 61.87
Earnings Date Feb 25, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 1,372
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol AB3A
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.